US 9,724,313

Application 13/315,397 · Granted Aug 8, 2017

Pharmaceutical composition for use in medical and veterinary ophthalmology

Estimated expiration

November 17, 2029

2y 362d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTRU2009000295: Resource not found (404)
Earliest effective filing
Jun 10, 2009
+ 20 years
Jun 10, 2029
PTA +160d
Nov 17, 2029
No TD
—
Final
Nov 17, 2029

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
December 9, 2011
Earliest effective filing
June 10, 2009
Issue date
August 8, 2017
PTA
+160 days
Base expiry (before PTA)
June 10, 2029

June 10, 2009 + 20 years = June 10, 2029 + 160 PTA days = November 17, 2029

  • Continuation-in-part of application PCTRU2009000295, filed Jun 10, 2009

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/315,397 · US 9,724,313

PatentReply compiles the prosecution history behind US 9,724,313: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9724313

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.